Breast Cancer

Breast Cancer Treatment

Cleveland Clinic's Breast Cancer Program is committed to providing patients with the best possible prevention, detection, and treatment options for breast disease. Breast cancer patients throughout main campus, regional hospitals and family health centers all received standardized care through care path guides and tumor board review. A multidisciplinary team comprising radiologists, pathologists, surgeons, plastic surgeons, medical oncologists, radiation oncologists, nurses, genetic counselors, psychologists, physical therapists, and social workers collaborates with each patient to develop a tailored care plan at National Accreditation Program for Breast Centers accredited sites throughout northeast Ohio.

Five-Year Overall Survival of Female Patients With All Stagesᵃ of Breast Cancer (N= 11171)

2009-2019

ᵃAJCC stage I-IV breast cancer

Five-Year Overall Survival of Female Patients With Breast Cancer by Raceᵃ (N= 10751)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
Caucasian (N= 9284)83456996565444572833
African-American (N= 1467)12971089881683450

ᵃSelf-Reported

Five-Year Overall Survival of Female Patients With Breast Cancer by Hormone Receptor Status (N= 8944)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
ER/PR Negative (N = 1750)154612811040803512
ER/PR Positive (N = 7072)63425409446935802388

ER= estrogen receptor, PR= progesterone receptor

Five-Year Overall Survival of Female Patients With Breast Cancer by HER2 Status (N= 7446)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
HER2 Negative (N = 6226)55404651365027611618
HER2 Positive (N = 1240)1130977794589350

HER2= human epidermal growth factor receptor 2

Five-Year Overall Survival of Female Patients With Stages I-III Breast Cancer by Estrogen Receptor, Progesterone Receptor, and HER2 Status (N= 9214)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
ER/PR Positive (N = 5897)52674445363428711849
HER2 Positive (N = 1071)989860706529320
Triple-Negative (N = 814)735609465341190

ER= estrogen receptor, HER2= human epidermal growth factor receptor 2, PR= progesterone receptor

Five-Year Overall Survival of Female Patients With Stage IV Breast Cancer by Estrogen Receptor, Progesterone Receptor, and HER2 Status (N = 413)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
ER/PR Positive (N = 264)2081631107241
HER2 Positive (N = 92)6960392011
Triple Negative (N = 57)2412843

ER= estrogen receptor, HER2= human epidermal growth factor receptor 2, PR= progesterone receptor

Five-Year Overall Survival of Female Patients With Stageᵃ 0 and I Breast Cancer (N= 6730)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
Stage 0 CC (N = 1847)167914491223979654
Stage I CC (N = 4883)42803490284822541424

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Stageᵃ IIA and IIB Breast Cancer (N= 3309)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
Stage IIA (N = 2282)21041856147011296793
Stage IIB (N = 1027)945814650500297

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Stageᵃ IIIA and IIIB Breast Cancer (N= 823)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
Stage IIIA (N = 590)552463350262153
Stage IIIB (N = 233)192140966740

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Late-Stage Breast Cancer (N= 677)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
Stage IIIC (N = 200)179134986844
Stage IV (N = 477)33924716010261

CC = Cleveland Clinic, NCDB = National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReferance group data from the National Cancer Database (Commission on Cancer of the American College of Surgeon and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010